Biometrics

Trust Stamp Announces the Continued Growth of its Patent Portfolio Encompassing AI-Powered Identity Solutions

Retrieved on: 
Monday, February 26, 2024

Atlanta, Georgia, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Trust Stamp (Nasdaq: IDAI), the Privacy-First Identity CompanyTM announced that on January 22nd, 2024 the USPTO issued a notice of allowance for utility patent application #17/324/544 entitled “Face Cover Compatible Biometrics and Processes for Generating and Using Same”.

Key Points: 
  • Atlanta, Georgia, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Trust Stamp (Nasdaq: IDAI), the Privacy-First Identity CompanyTM announced that on January 22nd, 2024 the USPTO issued a notice of allowance for utility patent application #17/324/544 entitled “Face Cover Compatible Biometrics and Processes for Generating and Using Same”.
  • Andrew Gowasack, Trust Stamp’s President, commented, “This unique technology was developed during the COVID pandemic, but the range of use cases is far wider than being able to identify a subject while wearing a surgical mask, and encompass both cultural and security considerations.
  • As a consequence of our microservice approach to software development, this capability can be implemented without significant changes to existing biometric authentication systems on a low-code or even no-code basis.”

Asia-Pacific Next-Generation IVD Research Report 2024: Market Size and Growth Potential 2020-2025 and 2026-2033 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 8, 2024

The "Asia-Pacific Next-Generation IVD Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia-Pacific Next-Generation IVD Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The Asia-Pacific (APAC) region is witnessing significant advancements and growth in the Next-Generation In Vitro Diagnostics (IVD) market.
  • The next-generation IVD market has been extensively segmented on the basis of various categories, such as type, end user, and country.
  • The next-generation IVD market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market.

Toshiba Global Commerce Solutions Sponsors Retailers Lounge at the Retail Technology Show 2024

Retrieved on: 
Thursday, March 7, 2024

Toshiba Global Commerce Solutions is proud to announce its continued partnership as the sponsor of the Retailers Lounge at the Retail Technology Show for the third consecutive year.

Key Points: 
  • Toshiba Global Commerce Solutions is proud to announce its continued partnership as the sponsor of the Retailers Lounge at the Retail Technology Show for the third consecutive year.
  • The Retailers Lounge is a space designed exclusively for retailers, providing a place for relaxation and refreshment during the bustling two-day event.
  • View the full release here: https://www.businesswire.com/news/home/20240307308907/en/
    At the Retail Technology Show, Toshiba Global Commerce Solutions will introduce some of the groundbreaking software and hardware solutions designed to revolutionise the retail experience and effectively tackle challenges such as labour shortages, loss prevention and inventory management.
  • ELERA® Commerce Platform: A comprehensive commerce platform with a suite of solutions that can free retailers from legacy constraints to optimise operations, streamline processes and enhance customer satisfaction.

Society for Laboratory Automation and Screening (SLAS) Selects CytoTronics’ Pixel System for 2024 New Product Award

Retrieved on: 
Tuesday, March 5, 2024

CytoTronics, Inc. , a pioneer of semiconductor-based platforms for discovery in cell biology, is pleased to announce that their Pixel ™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS).

Key Points: 
  • CytoTronics, Inc. , a pioneer of semiconductor-based platforms for discovery in cell biology, is pleased to announce that their Pixel ™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS).
  • Award selection was announced at the SLAS2024 International Conference and Exhibition in Boston, MA on February 6th, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240305158077/en/
    CytoTronics' Pixel™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS).
  • Front-runners are interviewed on-site at the conference by a panel of industry veterans with deep expertise in laboratory automation and screening techniques to determine final award recipients.

Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease

Retrieved on: 
Monday, March 4, 2024

The FDA’s Breakthrough Device designation is granted to products that have the potential to offer more effective diagnosis of life-threatening diseases with an unmet medical need.

Key Points: 
  • The FDA’s Breakthrough Device designation is granted to products that have the potential to offer more effective diagnosis of life-threatening diseases with an unmet medical need.
  • The Simoa p-Tau 217 test described in the Breakthrough Device application is a semi-quantitative in vitro diagnostic immunoassay intended for the measurement of p-Tau 217 concentration in plasma using the Quanterix HD-X immunoassay system.
  • The Breakthrough Device designation for the p-Tau 217 test underscores its potential to significantly impact Alzheimer's disease (AD) diagnosis and treatment.
  • However, Breakthrough Device designation does not guarantee that the FDA review and approval process will be shortened or that an application will be approved.

Children’s Hospital Los Angeles Neurologist Honored With Prestigious Research Award

Retrieved on: 
Monday, March 4, 2024

Children’s Hospital Los Angeles (CHLA) neurologist Shafali Spurling Jeste, MD , has been named the 2024 recipient of the prestigious Martha Bridge Denckla Award from the Child Neurology Society.

Key Points: 
  • Children’s Hospital Los Angeles (CHLA) neurologist Shafali Spurling Jeste, MD , has been named the 2024 recipient of the prestigious Martha Bridge Denckla Award from the Child Neurology Society.
  • View the full release here: https://www.businesswire.com/news/home/20240304251113/en/
    Children's Hospital Los Angeles Neurologist Shafali Spurling Jeste, MD, earns the Martha Bridge Denckla Award from the Child Neurology Society.
  • A Board-certified pediatric neurologist, Dr. Jeste has authored and contributed to more than 200 journal papers, editorials, chapters and abstracts.
  • She completed an internship, residency and a fellowship in behavioral child neurology at Boston Children’s Hospital.

Identiv Launches Innovative ScrambleFactor Reader with Biometrics and Multi-Factor Authentication for Secure Federal Government Access Control

Retrieved on: 
Monday, March 4, 2024

The ScrambleFactor reader reimagines secure entry for the federal market with fingerprint biometrics and a state-of-the-art LCD touchscreen keypad, integrating multiple authentication methods to deliver unparalleled security, speed, functionality and convenience.

Key Points: 
  • The ScrambleFactor reader reimagines secure entry for the federal market with fingerprint biometrics and a state-of-the-art LCD touchscreen keypad, integrating multiple authentication methods to deliver unparalleled security, speed, functionality and convenience.
  • ScrambleFactor is the latest addition to Identiv’s award-winning access control portfolio, offering federal users up to three-factor authentication suitable for the most secure applications.
  • ScrambleFactor exemplifies our dedication to innovation, providing a secure, user-friendly, and future-proof access control solution.”
    Get a live demo of ScrambleFactor at ISC West 2024 in Identiv booth 12089.
  • ScrambleFactor is designed for the U.S. federal government, offering a sophisticated solution for agencies and organizations looking to upgrade their access control systems with the latest in security technology.

SmartMetric the Maker of Biometric Fingerprint Activated Credit Cards Reports up to 80% of Credit Cards Have Been Compromised

Retrieved on: 
Friday, March 1, 2024

This allows the SmartMetric biometric card to be able to used “anywhere and anytime” a card holder wants to use their new biometric card.

Key Points: 
  • This allows the SmartMetric biometric card to be able to used “anywhere and anytime” a card holder wants to use their new biometric card.
  • “With so many credit card data breaches leaving a card holders credit card information in the hands of card fraud criminals, the use of on card biometric identity validation security, has become a necessity,“ said SmartMetric’s President and CEO, Chaya Hendrick.
  • 2
    Market research has shown that 70% of current credit card users are willing to pay $70.00 for a biometric secured credit card.
  • To view the SmartMetric Biometric Card please follow this link - Video of the SmartMetric Biometric Card .

Eurofins Discovery Introduces Innovative DiscoveryAI SAFIRE: A New AI-Driven Platform for Drug Discovery Trained Using Proprietary Datasets

Retrieved on: 
Thursday, February 29, 2024

Eurofins Discovery , an industry-leading provider of products and services for drug discovery research, today announced the launch of DiscoveryAI SAFIRE (Suite of ADMET Predictions For In Silico Refinement and Evaluation).

Key Points: 
  • Eurofins Discovery , an industry-leading provider of products and services for drug discovery research, today announced the launch of DiscoveryAI SAFIRE (Suite of ADMET Predictions For In Silico Refinement and Evaluation).
  • SAFIRE is an advanced platform that leverages proprietary datasets, artificial intelligence (AI), and machine learning (ML), offering a unique capability for expediting discovery.
  • It’s proven effective in accelerating drug discovery projects from initial hit discovery through to lead optimization.
  • For more details about SAFIRE’s benefits and significant value to the drug discovery community, visit eurofinsdiscovery.com/safire .